Anaplastic Large Cell Lymphoma (ALK+/ALK−): Difference between revisions
| [pending revision] | [pending revision] |
| Line 22: | Line 22: | ||
|None | |None | ||
|} | |} | ||
==Definition / Description of Disease== | ==Definition / Description of Disease== | ||
Anaplastic large cell lymphoma (ALCL) is a distinctive CD30-positive peripheral T-cell lymphoma that is rare in the CNS and is separated into two distinct types: ALK-positive (ALK+ ALCL) and ALK-negative (ALK− ALCL). | |||
==Synonyms / Terminology== | ==Synonyms / Terminology== | ||
None | |||
==Epidemiology / Prevalence== | ==Epidemiology / Prevalence== | ||
ALK+ ALCL occurs from early childhood to young adulthood with a male preponderance. | |||
ALK− ALCL affects adults (median age: 65 years), also with a male preponderance. | |||
==Clinical Features== | ==Clinical Features== | ||
{| class="wikitable" | {| class="wikitable" | ||
|'''Signs and Symptoms''' | |'''Signs and Symptoms''' | ||
| | |Headache, seizures, nausea, fever, or a combination | ||
|- | |- | ||
|'''Laboratory Findings''' | |'''Laboratory Findings''' | ||
| Line 47: | Line 40: | ||
|} | |} | ||
==Sites of Involvement== | ==Sites of Involvement== | ||
ALK+ ALCL occurs as single or multiple supratentorial parenchymal lesions with or without infratentorial involvement, and rarely with spinal cord involvement. Extension to involve the meninges and (rarely) the skull can occur. | |||
ALK− ALCL occurs as single or multiple lesions, usually supratentorial | |||
==Morphologic Features== | ==Morphologic Features== | ||
ALK+ ALCL shows a diffuse proliferation of large atypical cells with abundant cytoplasm, including hallmark cells with bean-shaped nuclei and an eosinophilic paranuclear area | |||
The cerebrospinal fluid may be involved. The large atypical neoplastic cells may have cytoplasmic azurophilic granules | |||
==Immunophenotype== | ==Immunophenotype== | ||
Put your text here and fill in the table | Put your text here and fill in the table | ||
| Line 56: | Line 53: | ||
!Finding!!Marker | !Finding!!Marker | ||
|- | |- | ||
|Positive (universal)|| | |Positive (universal)||CD30+, ALK+, and EMA+, may express one or more T-cell antigens | ||
|- | |- | ||
|Positive (subset)||EXAMPLE CD2 | |Positive (subset)||EXAMPLE CD2 | ||
| Line 64: | Line 61: | ||
|Negative (subset)||EXAMPLE CD4 | |Negative (subset)||EXAMPLE CD4 | ||
|} | |} | ||
==Chromosomal Rearrangements (Gene Fusions)== | ==Chromosomal Rearrangements (Gene Fusions) ALK+ ALCL == | ||
Put your text here and fill in the table | Put your text here and fill in the table | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 74: | Line 71: | ||
!Notes | !Notes | ||
|- | |- | ||
| | |t(2;5)(p23;q35) ||''NPM1''::''ALK'' fusion | ||
|5' NPM1::3' ALK on der(5). constitutive activation of the catalytic domain of ALK. Kinase function activated by oligomerization of NPM1::ALK mediated by the NPM1 portion||EXAMPLE 30 to 50% of ALCL | |||
(COSMIC) | |||
(add reference) | |||
|Yes | |||
|Yes | |Yes | ||
|Yes | |Yes | ||
|EXAMPLE | |EXAMPLE | ||
The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). | The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). | ||
Localized in both cytoplasm and nucleus. | |||
In translocations other than the t(2;5), i.e. in t(2;Var) involving various partners and ALK, the fusion protein has a cytoplasmic localization; they are therefore called "cytoplasm only" ALK+ ALCL. | |||
|- | |||
|t(X;2)(q11;p23) | |||
| | |||
|5'MSN:: 3'ALK | |||
|very rare, one case reported | |||
| | |||
| | |||
| | |||
|For the t(X;2) translocation, localization is restricted to the membrane. | |||
|- | |||
|t(1;2)(q25;p23) | |||
| | |||
|5'TPM3::3'ALK | |||
|rare, four cases reported | |||
| | |||
| | |||
| | |||
|TPM3::ALK is constitutively activated | |||
|- | |||
|inv(2)(p23q35) | |||
| | |||
|5'ATIC::3'ALK | |||
|rare | |||
| | |||
| | |||
| | |||
|ider(2)(q10)inv(2) has been found in some cases, carrying 2 additional copies of the ATIC::ALK hybrid gene; frequent complex karyotypes | |||
|- | |||
|t(2;3)(p23;q21) | |||
| | |||
|5'TFG::3-ALK | |||
|very rare, two cases reported | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|t(2;17)(p23;q23) | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|t(2;19)(p23; p13.1) | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|t(2;22)(p23;q11.2) | |||
| | |||
|5'CLTCL1::3'ALK | |||
|very rare, one or two cases | |||
| | |||
| | |||
| | |||
|the localization is restricted to granules (vesicles) in the cytoplasm | |||
|} | |} | ||
==Individual Region Genomic Gain/Loss/LOH== | ==Individual Region Genomic Gain/Loss/LOH== | ||
| Line 128: | Line 196: | ||
!Notes | !Notes | ||
|- | |- | ||
| | |Complex Karyotype | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
|- | |||
| +7 found in 20% of cases | |||
| | |||
| | |||
| | |||
|EXAMPLE: | |EXAMPLE: | ||
See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference). | See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference). | ||
|- | |||
|<nowiki>+9 in 5 to 10% of cases.</nowiki> | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|<nowiki>+X in 5 to 10% of cases.</nowiki> | |||
| | |||
| | |||
| | |||
| | |||
|} | |} | ||
==Gene Mutations (SNV/INDEL)== | ==Gene Mutations (SNV/INDEL)== | ||
| Line 183: | Line 268: | ||
|} | |} | ||
==Genetic Diagnostic Testing Methods== | ==Genetic Diagnostic Testing Methods== | ||
FISH w/ ALK BA probe | |||
==Familial Forms== | ==Familial Forms== | ||
Put your text here | Put your text here | ||